Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DuPont/Barr Enter Into Legal Truce With Five Product Promotion Accord

Executive Summary

DuPont expects to begin marketing a Barr-developed oncology product in the first quarter of 2001 under an agreement reached by the two companies in their Coumadin dispute.

You may also be interested in...



Pfizer’s Omnitrope Options Include Approval Challenge, Substitutability Fight

Pfizer's response to the approval of Sandoz' Omnitrope could signal the extent to which industry gauges the legality of approving follow-on biologics under the 505(b)(2) pathway

Pfizer’s Omnitrope Options Include Approval Challenge, Substitutability Fight

Pfizer's response to the approval of Sandoz' Omnitrope could signal the extent to which industry gauges the legality of approving follow-on biologics under the 505(b)(2) pathway

Bristol Buys DuPont: Re-Enters Imaging Agents, Adds To HIV Line

Bristol-Myers Squibb will re-enter the radiopharmaceutical business via the acquisition of DuPont Pharma.

Related Content

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel